On Tuesday, Tribune Media Co (NYSE:TRCO)’s shares declined -2.51% to $55.16.
On April 20, Tribune Media Co (TRCO), declared it will report financial results for the three months ended March 29, 2015 before the market opens on Friday, May 8, 2015. The Company will conduct a conference call at 8:00 a.m. ET.
Tribune Media Company, through its auxiliaries, operates as a media and entertainment company in the United States. The company operates through two segments, Television and Entertainment, and Digital and Data. The Television and Entertainment segment provides news, entertainment, and sports programming through Tribune Broadcasting local television stations, counting FOX television associates, CW television associates, CBS television associates, ABC television associates, NBC television associates, and independent television stations; and television series and movies on WGN America, a national general entertainment network.
Diamond Offshore Drilling Inc (NYSE:DO)’s shares dropped -2.50% to $30.09, during the last trading session on Tuesday.
On April 7, Loews Corporation is a diversified company with three publicly-traded auxiliaries: CNA Financial Corporation (CNA), Diamond Offshore Drilling, Inc. (DO) and Boardwalk Pipeline Partners, LP (BWP); and one wholly owned partner, Loews Hotels & Resorts.
Loews Corporation (NYSE:L) will report first quarter 2015 financial results on Monday, May 4, 2015. A conference call for analysts and investors will start at 11:00 a.m. EDT and will be hosted by the Company’s chief executive officer, James S. Tisch, and chief financial officer, David B. Edelson.
Diamond Offshore Drilling, Inc. provides contract drilling services to the energy industry worldwide. The company provides services in floater market, such as ultra-deepwater, deepwater, and mid-water; and non-floater or jack-up market. It operates a fleet of 38 offshore drilling rigs, which comprise 27 semisubmersibles, counting 1 under construction; 6 jack-ups; and 5 dynamically positioned drillships, counting 1 under construction.
Horizon Pharma PLC (NASDAQ:HZNP), ended its Tuesday’s trading session with -2.47% loss, and closed at $30.86.
Yesterday, Horizon Pharma PLC (NASDAQ:HZNP), declared the closing of its underwritten public offering of 17,652,500 of its ordinary shares at a price to the public of $28.25 per share. This comprises the exercise in full by the underwriters of their option to purchase up to 2,302,500 additional ordinary shares. The aggregate net proceeds to Horizon from this offering were about $475.2 million, after deducting underwriting discounts and other offering expenses payable by Horizon.
Citigroup, Jefferies LLC, Cowen and Company, LLC and Morgan Stanley & Co. LLC acted as joint book-running managers for this offering.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. It offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
